ABSTRACT
The authors report the case of an otherwise healthy 65-year-old man who presented with an acute right abducens nerve palsy 3 days after receiving the second dose of the AstraZeneca coronavirus disease 2019 (COVID-19) vaccine. Abducens nerve palsies typically results from microvascular disease or compressive tumors, although they are known to arise following routine vaccinations. Given the lack of preexisting risk factors, normal computed tomography scan results, and the timing of the symptoms, the abducens nerve palsy was believed to be related to the vaccination. This report highlights the potential neurologic adverse effects associated with COVID-19 vaccines. [J Pediatr Ophthalmol Strabismus. 2021;58(6):e49-e50.].
Subject(s)
Abducens Nerve Diseases , COVID-19 , Abducens Nerve Diseases/chemically induced , Abducens Nerve Diseases/diagnosis , Aged , COVID-19 Vaccines , Humans , Male , SARS-CoV-2ABSTRACT
This is a case report of central retinal vein occlusion (CRVO) associated with COVID-19 treated with oral aspirin therapy. A 56-year-old woman reported decreased vision in her left eye. Her left eye vision was 6/18, N10. Anterior segment was within normal limits. Left eye fundus was suggestive of CRVO and macular oedema. Optical coherence tomography showed cystoid macular oedema and neurosensory detachment. Blood work-up revealed elevated D-dimer levels and erythrocyte sedimentation rate (ESR). She was started on treatment with low-dose aspirin 150 mg/day. After 1 month, her vision improved to 6/6, N6. Left eye fundus showed reduced retinal haemorrhages and complete resolution of macular oedema. Her repeat blood work-up showed reduced D-dimer and ESR levels. The patient was asked to be reviewed after 3 months. This case highlights that specific treatment for reducing the hypercoagulable state caused by COVID-19 with oral aspirin therapy can result in complete resolution of CRVO macular oedema.